Clinical patients typically have multiple ABC transporters overexpressed, such as in patients with acute myeloid leukemias, rendering the use of reversal agents that exclusively target a single ABC transporter ineffective. The gene discussed is ABCG2; the disease is acute myeloid leukemia.